Racing for a COVID-19 Vaccine. Accelerating Vaccine Development in a Pandemic

Products and Solutions for Vaccine Development in Virus Outbreaks

For the last decade, we at Sartorius have been collaborating with and supplying our biopharmaceutical customers, helping enable them to successfully manufacture vaccines for infectious disease outbreaks and pandemics like Ebola, Zika, and H1N1. We bring our experience and solution portfolio to help our customers at different stages of vaccine production against the novel SARS-CoV-2 virus. We understand the urgency of the situation, and we believe that we can help our customers manage various risks inherent in vaccine discovery and production while maintaining quality and flexibility at an accelerated speed.


Contact a Vaccine Specialist

Here Are Some Ways We Are Working With Our Customers to Expedite Vaccine Production

Accelerating Vaccine Development With Speed and Safety

In order to secure funding and IND approval for a COVID-19 vaccine candidate, we know that speed is of essence. Our application experts provide specific insights on how to set-up processes and equipment to avoid hurdles which can slow you down. Our media and biosafety testing services further ensure safety and quality of the end product and the manufacturing process helping you gain IND approval and funding.


Contact a Vaccine Specialist

Sartorius Vaccine Solutions

Ambr®

High throughput process development equipment

Learn More

MODDE

High throughput process development equipment

Learn More

Virus Counter®

With the Virus Counter® 3100 platform, use this rapid, no wash labeling procedure and take virus quantification to new levels of accuracy, speed,...

Learn More

Services | Testing

Biosafety testing and process characterization services

Learn More

Accelerating Vaccine Production and Availability While Minimizing Manufacturing Risk​

In order to develop a safe and effective vaccine, we know that rapid scale-up to large-scale production needs to be achieved by strategically balancing risks and speed. Our application experts and integrated solutions team can help you design your facility to ramp-up production or adapt an existing facility so that you can maximize yield while decreasing footprint and Capex.


The New Biostat STR® Generation 3  bioreactor offers seamless scalability as well as perfusion capabilities suited for process intensification​.


Contact a Vaccine Specialist

At the same time we offer two means for you to minimize your supply chain risk:​

  1. Our industry-leading Assurance of Quality Supply (AoQS) is built on partnerships, quality agreements, and supply contracts with our suppliers to achieve tight specifications and controls of our resins and films. The control of our entire supply chain and manufacturing process is your best guarantee of consistent quality, change control and business continuity.​
  2. Adoption of our Pre-Designed Solutions (PDS) set of consumables ensures that you reduce lead times by using standard solutions. The PDS solutions have a comprehensive listing of parts and specifications so that you can rest assured that no missing critical components will cause an expensive production delay.​

Sartorius Vaccine Solutions

Biostat STR® Gen. 3

Engineered for Ultimate Upstream Performance

Learn More

Tangential Flow Filtration

Crossflow Cassettes and Systems for Highest Product Yields

Learn More
Flexsafe Pro Mixer for Single Use Mixing

Flexsafe® Pro Mixer

The Fast, Flexible and Intelligent Single-Use Mixer for All Mixing Steps in cGMP Bioprocessing

Flexsafe® Pro Mixer

Freeze & Thaw

Solving Complex Product Transfers With Our Freeze & Thaw Celsius® Solutions

Learn More

Accelerated and Flexible Manufacturing of High-Quality Vaccines​

We know that patients and healthcare professionals trust you to develop safe and efficacious vaccines. You can rely on us to help you scale-up your process to produce billions of doses for large-scale production while maintaining quality standards.​

  • Maintaining quality through process monitoring and control: Sartorius offers advanced sensors and process analytical technology through our BioPAT® toolbox as well as SIMCA® software so that you can monitor and control quality without impacting yield or process efficiency.
  • Flexibility to rapidly respond to changing demand: Sartorius offers both upstream and downstream products that allow you to rapidly scale-up, scale-down or scale-out as well as modular systems that fit multiple unit operations.


Contact a Vaccine Specialist

Sartorius Vaccine Solutions

Biostat STR® Gen. 3

Engineered for Ultimate Upstream Performance

Learn More

Sartobind® Cassettes

Learn More
Flexsafe Pro Mixer for Single Use Mixing

Flexsafe® Pro Mixer

The Fast, Flexible and Intelligent Single-Use Mixer for All Mixing Steps in cGMP Bioprocessing

Flexsafe® Pro Mixer

Flexact®️ Modular | Single-use Automated Solutions

Learn More

Vaccine Development Platforms

As the industry is racing to develop a vaccine, we want to ensure access to relevant technical information in a convenient and straightforward format. Our interactive process flow-chart provides an overview of various vaccine platforms that could be used for creating a COVID-19 vaccine. Explore our generic processes for viral vector vaccines, attenuated and inactivated viral vaccines, click on each step to reveal the specific challenges, and discover how Sartorius solutions meet those needs.

Explore our Vaccine Development Portfolio

On-Demand Webinars:

Sartorius has presented its capacity to support the industry to develop and manufacture a COVID-19 vaccine in a series of webinars. From processes overviews to deep dives into specific technologies and Services, listen to our experts and feel free to contact us to engage in further discussions.

Expediting Viral-Based Vaccines Development in Upstream Processing

Watch Webinar Online

Expediting Viral-Based Vaccines Development in Downstream Processing

Watch Webinar Online

Accelerating Vaccine Development with Standard Single-Use Solutions

Watch Webinar Online

Flexible and Scalable Strategies for Upstream Vaccine Development

Watch Webinar Online

Covid-19: Integrated Solutions to Accelerate Vaccine Production

Watch Webinar Online

Viral Vector Based Vaccine Development for Covid-19

Watch Webinar Online

Sartobind® Membrane Chromatography for Virus Purification

Watch Webinar Online

Protein Expression Platform

Fast Development of Coronavirus Vaccines

Watch Webinar Online

Virus Counter Platform

Accelerate Vaccine Development With Rapid Total Particle Quantification

Watch Webinar Online

Virus Expression Platform

Fast Development of Coronavirus Vaccines

Watch Webinar Online

How to Use Data Analytics for Accelerating Vaccine Development

Watch Webinar Online

A Data Driven Approach to Vaccine Scale-up and Tech Transfer

Watch Webinar Online

Resources

Success at Speed: Digging into Accelerated Vaccine Development - Part 1 - The Need for Speed and Safety

PDF | 679.2 KB

Success at Speed: Digging into Accelerated Vaccine Development - Part 2 - Regulatory Considerations

PDF | 607.7 KB

Success at Speed: Digging into Accelerated Vaccine Development - Part 3 - Vaccine Modalities

PDF | 730.6 KB

Success at Speed: Digging into Accelerated Vaccine Development - Part 4 – Commercial Manufacturing

PDF | 977.6 KB

Success at Speed: Digging into Accelerated Vaccine Development Part 5 – Reducing Costs

PDF | 1.1 MB

Whitepaper: Integrated Technologies to Accelerate Process Intensification for Viral Vaccine Manufacturing

PDF | 1.1 MB

Adenovirus Downstream Process Intensification Implementation of a Membrane Adsorber

PDF | 222.9 KB

Poster: Rapid Total Particle Quantification for Viral Families With High Potential for Pathogenic Emergence

PDF | 1.5 MB

Design of Experiments for Optimal Production of Malaria Vaccines With Pichia Pastoris

PDF | 2.7 MB

Comparing Multiuse and Single-Use Bioreactors for Virus Production

PDF | 515.6 KB

Enabling Viral Vaccine Production: Implementing Process-Scale Adenovirus Purification with a Single-Use Platform

PDF | 410.4 KB

ABL Europe’s New Production Facility for the GMP Manufacture of Viral Vectors

PDF | 7.6 MB

Contact a Vaccine Specialist